Chen Mei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chen Mei has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Yanling Ren
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 shared publications - Hongyan Tong
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 shared publications - Jie Jin
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications - Xinping Zhou
Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou People's Republic of China
3 shared publications Li Ye
Department of Hematology the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publicationsLingxu Jiang
Department of Hematology the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Comparable transplant outcomes with a decitabine-based reduced-toxicity regimen versus modified BUCY in older or frail MDS patients: A retrospective analysis of real-world practice
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for myelodysplastic syndromes (MDS), yet conventional myeloablative conditioning is highly toxic in elderly or frail patients. Objectives: To compare a decitabine-based reduced-toxicity conditioning (RTC) regimen with modified BUCY in higher-risk MDS patients undergoing allo-HSCT in a real-world setting. Design: Single-center retrospective cohort study. Methods: We retrospectively analyzed 82 consecutive MDS patients undergoing first allo-HSCT between September 2022 and June 2025. Thirty-six patients received decitabine-based RTC (decitabine 20 mg/m 2 /day ×3 days with reduced-dose busulfan and fludarabine), while 46 received modified BUCY. End points were overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). Results: The RTC group had higher baseline risks, including older age (median 57 vs. 53 years, P<0.01), higher HCT-CI scores (HCT-CI≥2: 44.4% vs. 10.9%, P<0.01), more prior debulking therapy (83% vs. 54%, P<0.01), and a trend for more TP53 mutations (22% vs. 13%, P=0.06). Despite greater frailty, 2-year outcomes were comparable: OS (80.5% vs. 75.1%, P=0.84), RFS (70.3% vs. 70.6%, P=0.79), CIR (13.5% vs. 9.6%, P=0.70), and NRM (16.1% vs. 22.0%, P=0.88). In multivariable models, the regimen was not significantly associated with OS (HR 0.35, 95% CI, 0.10–1.17; P=0.09), RFS (HR, 0.67; 95% CI, 0.23–1.92; P=0.45). HCT-CI ≥2 predicted higher mortality (HR, 6.32; 95% CI, 1.78–22.37; P=0.004). Conclusion: Despite the higher baseline frailty, decitabine-based RTC regimen achieved survival outcomes comparable to modified BUCY in MDS patients. These findings suggest its potential to expand transplant eligibility, warranting prospective studies.
- 17 November 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessComparable transplant outcomes with a decitabine-based reduced-toxicity regimen versus modified BUCY in older or frail MDS patients: A retrospective analysis of real-world practice
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option for myelodysplastic syndromes (MDS), yet conventional myeloablative conditioning is highly toxic in elderly or frail patients. Objectives: To compare a decitabine-based reduced-toxicity conditioning (RTC) regimen with modified BUCY in higher-risk MDS patients undergoing allo-HSCT in a real-world setting. Design: Single-center retrospective cohort study. Methods: We retrospectively analyzed 82 consecutive MDS patients undergoing first allo-HSCT between September 2022 and June 2025. Thirty-six patients received decitabine-based RTC (decitabine 20 mg/m 2 /day ×3 days with reduced-dose busulfan and fludarabine), while 46 received modified BUCY. End points were overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). Results: The RTC group had higher baseline risks, including older age (median 57 vs. 53 years, P<0.01), higher HCT-CI scores (HCT-CI≥2: 44.4% vs. 10.9%, P<0.01), more prior debulking therapy (83% vs. 54%, P<0.01), and a trend for more TP53 mutations (22% vs. 13%, P=0.06). Despite greater frailty, 2-year outcomes were comparable: OS (80.5% vs. 75.1%, P=0.84), RFS (70.3% vs. 70.6%, P=0.79), CIR (13.5% vs. 9.6%, P=0.70), and NRM (16.1% vs. 22.0%, P=0.88). In multivariable models, the regimen was not significantly associated with OS (HR 0.35, 95% CI, 0.10–1.17; P=0.09), RFS (HR, 0.67; 95% CI, 0.23–1.92; P=0.45). HCT-CI ≥2 predicted higher mortality (HR, 6.32; 95% CI, 1.78–22.37; P=0.004). Conclusion: Despite the higher baseline frailty, decitabine-based RTC regimen achieved survival outcomes comparable to modified BUCY in MDS patients. These findings suggest its potential to expand transplant eligibility, warranting prospective studies.
- Open Access
- 8 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation
In haploidentical hematopoietic stem cell transplantation, preexisting donor-specific anti-HLA antibodies (DSAs) in recipients have been associated with graft rejection, poor graft function (PGF), and unfavorable clinical outcomes, with relatively well-established consensus strategies for its management. However, reports on the emergence of de novo DSAs after transplantation and the corresponding therapeutic approaches remain limited. Here, we describe a case of a 14-year-old patient with myelodysplastic syndrome who developed de novo DSAs as early as day 15 post-transplantation, with a peak mean fluorescence intensity of 12,280, which was associated with PGF. To reduce DSA levels, plasma exchange combined with intravenous immunoglobulin and rituximab was administered, followed by a series of interventions including mesenchymal stem cell infusion. These measures facilitated graft function recovery, controlled transplant-related complications, and ultimately led to successful engraftment.
- 8 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessEarly-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation
In haploidentical hematopoietic stem cell transplantation, preexisting donor-specific anti-HLA antibodies (DSAs) in recipients have been associated with graft rejection, poor graft function (PGF), and unfavorable clinical outcomes, with relatively well-established consensus strategies for its management. However, reports on the emergence of de novo DSAs after transplantation and the corresponding therapeutic approaches remain limited. Here, we describe a case of a 14-year-old patient with myelodysplastic syndrome who developed de novo DSAs as early as day 15 post-transplantation, with a peak mean fluorescence intensity of 12,280, which was associated with PGF. To reduce DSA levels, plasma exchange combined with intravenous immunoglobulin and rituximab was administered, followed by a series of interventions including mesenchymal stem cell infusion. These measures facilitated graft function recovery, controlled transplant-related complications, and ultimately led to successful engraftment.
- 3 February 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (2) , e70043
Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts
This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate‐to‐severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression‐free survival (PFS) (6.6 vs. 15.2 months; p = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; p < 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS‐EB) subtypes, individuals with MF2‐3 exhibited shorter OS (4.8 vs. 11.7 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than those in patients with MF0‐1. However, individuals with MF0‐1 and MF2‐3 showed similar OS and PFS rates among the patients with the MDS non‐excess blast (MDS‐nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS‐f) had a shorter OS (5.6 vs. 13.8 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than MDS with increased blasts (MDS‐IB) subtypes. Our study reveals the unique features of patients with MDS‐MF2‐3 and validates the refinements made in the 5th edition of the WHO proposal.
- 3 February 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (2) , e70043
Moderate‐To‐Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts
This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate‐to‐severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression‐free survival (PFS) (6.6 vs. 15.2 months; p = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; p < 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS‐EB) subtypes, individuals with MF2‐3 exhibited shorter OS (4.8 vs. 11.7 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than those in patients with MF0‐1. However, individuals with MF0‐1 and MF2‐3 showed similar OS and PFS rates among the patients with the MDS non‐excess blast (MDS‐nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS‐f) had a shorter OS (5.6 vs. 13.8 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than MDS with increased blasts (MDS‐IB) subtypes. Our study reveals the unique features of patients with MDS‐MF2‐3 and validates the refinements made in the 5th edition of the WHO proposal.
- Open Access
- 19 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (16) , eadi1782
RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that necroptosis, a form of programmed cell death, contributed to the antileukemia activity of R-2HG. Mechanistically, R-2HG competitively inhibited the activity of lysine demethylase 2B (KDM2B), an α-ketoglutarate–dependent dioxygenase. KDM2B inhibition increased histone 3 lysine 4 trimethylation levels and promoted the expression of receptor-interacting protein kinase 1 (RIPK1), which consequently caused necroptosis in AML cells. The expression of RIPK3 was silenced because of DNA methylation in IDH-mutant (mIDH) AML cells, resulting in R-2HG resistance. Decitabine up-regulated RIPK3 expression and repaired endogenous R-2HG–induced necroptosis pathway in mIDH AML cells. Together, R-2HG induced RIPK1-dependent necroptosis via KDM2B inhibition in AML cells. The loss of RIPK3 protected mIDH AML cells from necroptosis. Restoring RIPK3 expression to exert R-2HG’s intrinsic antileukemia effect will be a potential therapeutic strategy in patients with AML.
- 19 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (16) , eadi1782
Open AccessRIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Mutant isocitrate dehydrogenases (IDHs) produce R-2-hydroxyglutarate (R-2HG), which inhibits the growth of most acute myeloid leukemia (AML) cells. Here, we showed that necroptosis, a form of programmed cell death, contributed to the antileukemia activity of R-2HG. Mechanistically, R-2HG competitively inhibited the activity of lysine demethylase 2B (KDM2B), an α-ketoglutarate–dependent dioxygenase. KDM2B inhibition increased histone 3 lysine 4 trimethylation levels and promoted the expression of receptor-interacting protein kinase 1 (RIPK1), which consequently caused necroptosis in AML cells. The expression of RIPK3 was silenced because of DNA methylation in IDH-mutant (mIDH) AML cells, resulting in R-2HG resistance. Decitabine up-regulated RIPK3 expression and repaired endogenous R-2HG–induced necroptosis pathway in mIDH AML cells. Together, R-2HG induced RIPK1-dependent necroptosis via KDM2B inhibition in AML cells. The loss of RIPK3 protected mIDH AML cells from necroptosis. Restoring RIPK3 expression to exert R-2HG’s intrinsic antileukemia effect will be a potential therapeutic strategy in patients with AML.
- 18 January 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (3) , 546-554
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study
The treatment of patients with refractory and/or relapsed (R/R) high‐risk myelodysplastic syndrome (HR‐MDS) remains a daunting clinical challenge. Venetoclax is a selective BCL‐2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of patients with R/R HR‐MDS receiving combination azacytidine (AZA) plus 15‐days duration of venetoclax (VEN‐15d) in order to determine their efficacy and toxicity in this context. We showed that the overall response rate was 57.2% (20/35) and the median over survival was 14 months in R/R MDS. The most common treatment‐emergent adverse events were peripheral blood cytopenias and infectious complications. Our retrospective study showed that the real‐world experience of treating R/R MDS with AZA plus VEN‐15d highlights an encouraging response rate with myelosuppression being the major toxicity. Of note, VEN‐15d with AZA may salvage patients failing to respond optimally to HMAs and reduce the disease‐burden for subsequent allogeneic stem cell transplantation in our analysis. These data of combination AZA plus VEN‐15d in R/R MDS warrant further prospective evaluation in clinical trials.
- 18 January 2023
- Published by Wiley in Hematological Oncology
- Vol. 41 (3) , 546-554
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study
The treatment of patients with refractory and/or relapsed (R/R) high‐risk myelodysplastic syndrome (HR‐MDS) remains a daunting clinical challenge. Venetoclax is a selective BCL‐2 inhibitor, which combined with hypomethylating agents (HMAs), increased responses and prolonged survival in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of patients with R/R HR‐MDS receiving combination azacytidine (AZA) plus 15‐days duration of venetoclax (VEN‐15d) in order to determine their efficacy and toxicity in this context. We showed that the overall response rate was 57.2% (20/35) and the median over survival was 14 months in R/R MDS. The most common treatment‐emergent adverse events were peripheral blood cytopenias and infectious complications. Our retrospective study showed that the real‐world experience of treating R/R MDS with AZA plus VEN‐15d highlights an encouraging response rate with myelosuppression being the major toxicity. Of note, VEN‐15d with AZA may salvage patients failing to respond optimally to HMAs and reduce the disease‐burden for subsequent allogeneic stem cell transplantation in our analysis. These data of combination AZA plus VEN‐15d in R/R MDS warrant further prospective evaluation in clinical trials.